- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06486636
Pericardiotomy in Cardiac Surgery (PRINCE)
Pericardiotomy in Cardiac Surgery Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 30% of cardiac surgical patients develop post-operative atrial fibrillation (POAF). Its incidence varies depending on the type of cardiac operation. POAF is associated with short- and long-term adverse events, including mortality, stroke, and heart failure. POAF has also been significantly associated with unplanned hospitalization for heart failure.
During cardiac surgery, pericardial fluid tends to collect posterior to the left atrium. Even small amounts of fluid may trigger atrial arrhythmias. A posterior left pericardiotomy is a surgical procedure that involves cauterizing an opening between the left inferior pulmonary vein and the diaphragm. This procedure may allow for more prolonged drainage of the pericardial fluid into the left pleural space. Recent research evidence found that posterior pericardiotomy was associated with a significantly lower incidence of POAF.
The existing data on posterior pericardiotomy is promising for a reduction in POAF. However, no high-quality study has demonstrated that this reduction improves clinical outcomes in the years after cardiac surgery. The PRINCE trial's long-term follow-up of patients randomized to left posterior pericardiotomy could conclusively demonstrate whether the relationship of POAF to post-discharge clinical outcomes is causal and modifiable.
The PRINCE trial will evaluate the effectiveness and safety of posterior left pericardiotomy in preventing POAF and improving post-discharge clinical outcomes in a broad spectrum of cardiac surgery patients.
The intervention under investigation is left posterior pericardiotomy which is compared to no posterior pericardiotomy during cardiac surgery. The early co-primary outcome is in-hospital POAF, and the late co-primary outcome is the hierarchical composite of time to all-cause death, time to ischemic stroke, time to systemic arterial embolism, time to unplanned hospital visit/readmission for cardiac reasons, and time to atrial fibrillation after index hospital discharge.
The study will enrol 1400 patients from 30 centres, globally. Follow-up visits will be performed in person or by telephone 1 and 6 months post-randomization (+7 days), and then every 6 months (+30 days) until an average follow-up of 5 years for the study participants (estimated to be 4 years after completion of enrolment).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Richard Whitlock
- Phone Number: 40306 9055274322
- Email: Richard.Whitlock@phri.ca
Study Contact Backup
- Name: PRINCE Coordinators
- Email: PRINCE@phri.ca
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- Medical University Vienna
-
Contact:
- Dr. Sigrid Sandner, MD
- Phone Number: +43 (0)1 40400-69895
- Email: sigrid.sandner@meduniwien.ac.at
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Recruiting
- Hamilton Health Sciences
-
Contact:
- Emilie Belley-Côté, MD, PhD, FRCPC
- Phone Number: 41147 (905) 527-4322
- Email: Emilie.Belley-Cote@phri.ca
-
-
-
-
-
Foggia, Italy, 71122
- Recruiting
- University of Foggia, Policlinico Foggia
-
Contact:
- Prof. Domenico Paparella, MD, PHD
- Phone Number: +39 0881 736145
- Email: domenico.paparella@unifg.it
-
-
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Weill Cornell Medicine
-
Contact:
- Dr. Mario Gaudino, MD, PhD
- Phone Number: 212-746-1815
- Email: mfg9004@med.cornell.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients greater than or equal to 18 years of age
- Requiring surgical intervention on the proximal aorta, cardiac valves, and/or coronary arteries
- Able to provide informed consent
Exclusion Criteria:
- History of atrial fibrillation or flutter
- Cardiac surgery procedures not included in the inclusion criteria (planned ventricular assistance device, aortic arch, transplantation surgery)
- Prior cardiac surgery requiring opening of the pericardium
- Previous surgical instrumentation of the left pleural cavity
- Patient undergoing minimally invasive cardiac surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Left Posterior Pericardiotomy Group
The surgeon will perform a left posterior pericardiotomy during the patient's cardiac surgery.
|
The surgeon will perform a left posterior pericardiotomy while the patient is on cardiopulmonary bypass.
A soft channel drain will be put into place at an angle directed toward the posterior pericardium.
The surgeon will grasp the pericardium and use cautery to make a 4- to 5-cm opening between the left inferior pulmonary vein and the diaphragm.
The previously prepared channel drain is cut to the desired length and placed through the pericardiotomy along the diaphragm and into the pleural space.
|
|
No Intervention: No Posterior Pericardiotomy Group
The surgeon will not perform a posterior pericardiotomy during the patient's cardiac surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hierarchical composite of all-cause death, ischemic stroke, systemic arterial embolism, unplanned hospital visit/readmission for cardiac reasons, and atrial fibrillation.
Time Frame: Over the duration of the follow-up period to a common end date (mean follow-up of 5 years).
|
Number of patients with a composite of all-cause death, ischemic stroke, systemic arterial embolism, unplanned hospital visit/readmission for cardiac reasons, and atrial fibrillation events, evaluated using the win ratio (thereby accounting for the difference in importance of these outcomes).
|
Over the duration of the follow-up period to a common end date (mean follow-up of 5 years).
|
|
In-hospital post-operative atrial fibrillation
Time Frame: Within 5 days after index cardiac surgery
|
Number of patients with post-operative atrial fibrillation within the first 5 days postoperatively or up to hospital discharge, whichever occurs first
|
Within 5 days after index cardiac surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-operative atrial fibrillation (POAF)
Time Frame: Over the duration of the follow-up period to a common end date (mean follow-up of 5 years).
|
Number of patients with post-operative atrial fibrillation
|
Over the duration of the follow-up period to a common end date (mean follow-up of 5 years).
|
|
Length of post-operative in-hospital stay
Time Frame: Over the duration of the follow-up period to a common end date (mean follow-up of 5 years).
|
Length of time the patient in hospital after their index cardiac surgery
|
Over the duration of the follow-up period to a common end date (mean follow-up of 5 years).
|
|
Pericardial effusion without tamponade
Time Frame: From index surgery completion to within 30 days of index surgery
|
Number of pericardial effusions that occur, excluding cardiac tamponade
|
From index surgery completion to within 30 days of index surgery
|
|
Death
Time Frame: From index surgery completion to within 30 days of index surgery
|
Occurrence of death
|
From index surgery completion to within 30 days of index surgery
|
|
Ischemic stroke or systemic arterial embolism
Time Frame: From index surgery completion to within 30 days of index surgery
|
Number of ischemic strokes or systemic arterial embolisms
|
From index surgery completion to within 30 days of index surgery
|
|
Hospital readmission or unplanned hospital visit
Time Frame: From index surgery completion to within 30 days of index surgery
|
Number of hospital readmissions or unplanned hospital visits
|
From index surgery completion to within 30 days of index surgery
|
|
Quality of life assessed by the European quality of life index version 5D (EQ-5D-5L) questionnaire
Time Frame: Over the duration of the follow-up (mean follow-up of 5 years)
|
The EQ-5D-5L consists of a descriptive system and the EQ visual analogue scale (EQ VAS) scale of 0-100 where the endpoints are labelled 'The best health you can image' and 'The worst health you can imagine'.
The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension is measured on a 5 point scale: no problems, slight problems, moderate problems, severe problems and extreme problems.
|
Over the duration of the follow-up (mean follow-up of 5 years)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with phrenic nerve injuries
Time Frame: Within 30 days of index surgery
|
Safety outcome
|
Within 30 days of index surgery
|
|
Number of patients with left pleural interventions
Time Frame: Within 30 days of index surgery
|
Safety outcome
|
Within 30 days of index surgery
|
|
Number of patients with esophageal injuries
Time Frame: Within 30 days of index surgery
|
Safety outcome
|
Within 30 days of index surgery
|
|
Number of patients requiring re-operation for bleeding
Time Frame: Within 48 hours of index surgery completion
|
Safety outcome
|
Within 48 hours of index surgery completion
|
|
Number of patients with cardiac tamponade
Time Frame: Within 30 days of index surgery
|
Safety outcome
|
Within 30 days of index surgery
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Richard Whitlock, Population Health Research Institute
- Principal Investigator: Emilie Belley-Côté, Population Health Research Institute
- Principal Investigator: Mario Gaudino, Weill Medical College of Cornell University
- Principal Investigator: Sigrid Sandner, Medical University Vienna
- Principal Investigator: Björn Redfors, Göteborg University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRINCE - 2024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Medtronic Cardiac Ablation SolutionsRecruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation | Atrial Fibrillation (AF)Australia, United States, France, Belgium, Switzerland, Czechia
-
China National Center for Cardiovascular DiseasesRecruitingAtrial Fibrillation Ablation | Atrial Fibrillation (AF) | Radiofrequency Catheter Ablation | Atrial Fibrillation Recurrent | Pulsed Field AblationChina
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Boston Scientific CorporationRecruitingAtrial Fibrillation (AF) | Persistant Atrial FibrillationUnited States, Spain, Belgium, France, Netherlands, Germany, Hong Kong
-
CortexAblacon, Inc.Active, not recruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Boston Scientific CorporationRecruitingParoxysmal Atrial Fibrillation | Persistent Atrial FibrillationHong Kong, Czechia, Croatia, Taiwan
-
Vivek ReddyBoston Scientific CorporationRecruitingParoxysmal Atrial Fibrillation | Persistent Atrial FibrillationUnited States
-
Navy General Hospital, BeijingNot yet recruitingAtrial Fibrillation (AF) | Atrial Fibrillation Burden
Clinical Trials on Left Posterior Pericardiotomy
-
Weill Medical College of Cornell UniversityCatholic University of the Sacred HeartCompletedAtrial FibrillationUnited States
-
Changhai HospitalNot yet recruitingAtrial Fibrillation (AF) | Cardiac EventsChina
-
Seoul National University HospitalCompletedCoronary Artery Disease | Pericardial Effusion | Atrial Fibrillation New OnsetSouth Korea
-
Chinese University of Hong KongTerminatedPericardial Effusion MalignantHong Kong
-
University Hospital Plymouth NHS TrustCompletedPersistent Atrial Fibrillation | Atrial Fibrillation AblationUnited Kingdom
-
Mayo ClinicCompleted
-
Taiz University - Faculty of MedicineCompletedPostoperative Atrial Fibrillation | Cardiac TamponadeYemen
-
Oxford University Hospitals NHS TrustCompletedAtrial FibrillationUnited Kingdom
-
University of RochesterPatient-Centered Outcomes Research InstituteEnrolling by invitationAtrial Fibrillation (AF)United States
-
Texas Cardiac Arrhythmia Research FoundationCatholic University of the Sacred Heart; Capital Medical University; Centro Cardiologico...Completed